Tezacaftor

CAT: 0804-HY-15448-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-15448-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Tezacaftor (VX-661) is a F508del CFTR corrector. It helps CFTR protein reach the cell surface. However, Ivacaftor (VX-770, HY-13017), a CFTR potentiator, helps to prolong the opening time of cell surface CFTR protein channels. Tezacaftor combining with Ivacaftor, shows potent efficacy against cystic fibrosis and diseases with homozygous for the CFTR Phe508del mutation. Moreover, Elexacaftor (VX-445, HY-111772) is also a CFTR corrector. Elexacaftor-Tezacaftor-Ivacaftor aims at with cystic fibrosis (CF) with at least one Phe508del mutation, often avoids the indication for lung transplantation[1][2][3][4].
CAS Number
[1152311-62-0]
Product Name Alternative
VX-661
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CFTR
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/VX-661.html
Purity
99.94
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(C1(C2=CC=C(OC(F)(F)O3)C3=C2)CC1)NC4=CC5=C(N(C[C@@H](O)CO)C(C(C)(C)CO)=C5)C=C4F
Molecular Formula
C26H27F3N2O6
Molecular Weight
520.50
Precautions
H302, H315, H319, H335
References & Citations
[1]Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation. April 18, 2013|[2]Taylor-Cousar JL, et al. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med. 2017 Nov 23;377 (21) :2013-2023. |[3]Burgel PR, et al. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Am J Respir Crit Care Med. 2021 Jul 1;204 (1) :64-73. |[4]Huang Y, et al. Elexacaftor/Tezacaftor/Ivacaftor Improved Clinical Outcomes in a Patient with N1303K-CFTR Based on In Vitro Experimental Evidence. Am J Respir Crit Care Med. 2021 Nov 15;204 (10) :1231-1235.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Launched

Alternative Products

CatalogName
TRC-T321510-10MGTezacaftor
TRC-T321512-0.5MGTezacaftor-D4
MF-0008895-01(Rac) -Tezacaftor
JH72184Tezacaftor (VX661)
MBS5817155(Rac)-Tezacaftor
90036926-25mgTezacaftor VX661
TRC-T254370-50MGTezacaftor Metabolite M1
TRC-D321511-1MGDibenzyloxy Tezacaftor-D4
510264Tezacaftor (VX-661)
RM-T720003-01Tezacaftor Impurity 3

Popular Products